<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798954</url>
  </required_header>
  <id_info>
    <org_study_id>SKT</org_study_id>
    <nct_id>NCT00798954</nct_id>
  </id_info>
  <brief_title>Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial</brief_title>
  <acronym>SINGLEKISS</acronym>
  <official_title>A Multi-center Trial to Evaluate Paclitaxel- and Sirolimus-eluting Stents in Provisional T-stenting With Kissing Balloon Technique in the Treatment of Bifurcation Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vulnerable Plaque Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vulnerable Plaque Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of DES have not diminished the need of improved treatment strategies , especially the
      treatment of bifurcation lesions still leave much to be clarified. Particularly, for
      bifurcation lesions where stenting the main branch could result in an obstruction of a vital
      side branch, many reports have been about using 2 drug-eluting stents. Resulting in less than
      favorable, target lesion revascularization (TLR) rates, with 10-15% for main branch and
      11-40% for side branch.

      In Japan, the PERFECT multi-center registry evaluated outcomes of single stenting plus
      kissing balloon technique after Directional Coronary Atherectomy (DCA) removal of tissue
      plaques. TLR rates for both main branch and side branch were a satisfactory 1.3%. However,
      the DCA technique is mainly suitable for proximal coronary artery lesions, and takes skilled
      operators.

      For the treatment of relatively distal bifurcation lesions, where first POBA is performed,
      then the lesion is stented, followed by kissing balloon technique to fully expand the side
      branch, is considered a viable treatment. The Toyohashi Heart Center outcomes from August
      2004 for this single stent and kissing ballooning technique, using the sirolimus-eluting
      stent on bifurcation lesions, achieved a satisfactory 5.2% TLR for both main and side
      branches, suggesting that using two stents may not be necessarily the ideal treatment.

      The paclitaxel-eluting stent is expected to become available in Japan from June 2007. This
      stent's cells can be expanded to a maximum of 3.5mm, which should provide a larger lumen
      access for side-branch treatment.

      As such, we developed this study to compare the outcomes of paclitaxel-eluting and
      sirolimus-eluting stents in bifurcation lesions that require side branch dilatation using the
      kissing ballooning technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary Endpoints Target lesion revascularization after one year

        2. Secondary Endpoints Secondary endpoints be evaluated in terms of safety and efficacy.

      2-1 Safety

        1. Major complications associated with procedure (death, QMI, CABG)

        2. Major complications at follow-up (within 9 months) (death, QMI, CABG)

        3. Target vessel revascularization (TVR) performed within 9 months 2-2 Efficacy

      1. Acute angiographic success

        -  Minimum lumen diameter (MLD)

           ・% stenosis 2. Angiographic success at follow-up

        -  Minimum lumen diameter (MLD)

           ・% stenosis

        -  Loss index

        -  Late loss
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>TAXUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting coronary stent (Cypher)</intervention_name>
    <description>Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.</description>
    <arm_group_label>Cypher</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent (TAXUS)</intervention_name>
    <description>Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.</description>
    <arm_group_label>TAXUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient Inclusion Criteria:

          1. Age ≥18 to &lt;81 years and are able to undergo CABG

          2. Females who are not pregnant

          3. Patients who present with angina symptoms or myocardial ischemia

          4. Patients available for post-procedural observation and coronary angiography at 9
             months

          5. Patients who have signed patient informed consent

        Angiographic Inclusion Criteria:

          1. Bifurcation lesion with ≥2.0mm side branch diameter as confirmed angiographically (the
             Duke Classification (see Reference 1)

          2. The target lesion without remote lesions in the same vessel.

          3. De novo lesion or non-stented restenosed lesion

          4. Lesion which is eligible for stent implantation

          5. Main branch reference vessel diameter of ≥2.5 mm by visual assessment

          6. If two or more bifurcated lesions are present in the reference lesion, the proximal
             lesion shall be included in this study.

        Exclusion Criteria:

        Patient Exclusion Criteria:

          1. Patients contraindicated for antiplatelet therapy or anticoagulant therapy

          2. Patients with significant allergic reaction to contrast medium

          3. Patients who are pregnant or may be pregnant

          4. Patients with left ventricle ejection fraction of &lt;30%

          5. Patients deemed inappropriate by physician

        Angiographic Exclusion Criteria:

          1. Main branch reference vessel diameter of ≥4.5 mm by angiography

          2. Bypass grafts lesions

          3. In-stent restenosis lesions

          4. Highly tortuous lesions of ≥60 degrees

          5. Highly calcified lesions in which full stent dilatation may not be possible

          6. The target lesion with remote lesions in the same vessel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenya Nasu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toyohashi Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuji Oikawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Higashi Cardiovascular Clinic</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4400836</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vulnerable Plaque Society</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4400850</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyohashi Heart Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4418530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Chiba Medical Center</name>
      <address>
        <city>Ichihara</city>
        <state>Chiba</state>
        <zip>2990111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southen Tohoku Research Institute</name>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <zip>9638563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Cardiovascular Center</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>3710004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kihara Junkanki Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chitose City Hospital</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>0668550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinko Kagogwa Hospital</name>
      <address>
        <city>Kakogawa</city>
        <state>Hyogo</state>
        <zip>6750115</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanda City Hospital</name>
      <address>
        <city>Sanda</city>
        <state>Hyogo</state>
        <zip>6691321</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>5980048</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Tokushukai Hospital</name>
      <address>
        <city>Matsubara</city>
        <state>Osaka</state>
        <zip>5800032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyou</state>
        <zip>1060032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Police Hospital</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>1028161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi Chuo Medical Center</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>1740051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>1600023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2008</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kenya Nasu</name_title>
    <organization>Toyohashi Heart Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

